Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AROMA registry of long-term Dupixent outcomes in chronic rhinosinusitis with nasal polyps
NL-OMON53573Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Descriptive summary of symptoms, health-related quality of life, and change over time and Descriptive summary of patient and disease characteristics. Started Jun 2023; status: recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NL-OMON53573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53573.